Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Trial to Evaluate the Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3205 Capsule in Subjects With Advanced Malignant Tumors

NCT07482592 is registered in ClinicalTrials.gov with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. as lead sponsor.

NCT NCT07482592
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07482592 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Trial to Evaluate the Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3205 Capsule in Subjects With Advanced Malignant Tumors
Lead sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
April 15, 2026
Completion date
December 31, 2028
Enrollment
156 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant cancer